Thank for system. company, recently This major grant year we everyone achieved momentous to today. for milestone B Epidural and you, assignment joining a of been the as with has physician a for Part David, our Medicare payment rate thanks CompuFlo the us
payers have to reimbursement by the ruling. pricing we technology understanding has methodical educate predictability, utility, able MAX, our As the thoroughly with closely that to have we with necessity also efficacy and jurisdictions, our medical known reported, contractors, J approach We've strategic. full the Medicare on to and and clinicians been ensuring technology, as of prior been to of previously the our safety, worked Medicare clinical CompuFlo jurisdictional document system, administrative engaging their
granted price Colombia Texas, approximately X/X the achievement. An conducted are New Medicare JMAC injection Epidural Arkansas, for the jurisdictions, across multiple procedures for chronic treatment. Maryland, of pain Colorado, of year including X procedures Delaware, Jersey, significant such X each estimated District in across Mississippi, these steroid favorable key accounting total States Pennsylvania, Louisiana, Mexico, This epidural back injection steroid performed million the regions states New a assignment as represents and Florida, Oklahoma, United
across rest patients to introduce also of throughout our is forward but work outcome major a from benefits [indiscernible] country. jurisdictions of Medicare step of among of more regions there's increasing represent With and believed for still and initial our technology, penetration these in technology. the We safety Medicare volume, clinical an to adoption million of only a alone. technology these our the approximately account of $XXX recognize the ahead positive practice The to market significant XX% up this not addressable validation these
in our point this turning targeted to crucial team continuing a proud marks and committed at U.S. to who milestone tirelessly I'm our reach are our achievement extremely efforts in have we journey. this entire additional worked of However, the [indiscernible]
In to whose represents within disciplined announce Jersey, expanding laser-focused of the in partnership and strategic to to partner. extensive are with key our reach commercial deep tandem sector, by an states Actual New relationships Axo's This Biologics, and with excited relationships the Florida. established and Texas a approach experience pain leveraging them we make collaboration this our clinician progress, [indiscernible] belonging the ideal management
a drive sales adoption System next growth aligning and confident that of collaboration our Epidural our patient will instead of and strategy, own partner more it the of building with outcomes. CompuFlo effectively. a This of large and sales enhance we the accelerate we specialized penetration marks By force, the distributor can phase are
We there a for believe federal agencies. other within is and CompuFlo market government also opportunity
As discussed to working approval the and we we advancing following past, are secure federal have the in initiatives approval SAM supply schedule. the within FSS,
market. government open FSS would approval the sizable up
the international to front. Turning
our CompuFlo. We expanding for distribution partners of network are
announce thoracic paretic with and relationships distributors Surveillance key independent proven and global Epidural Health of received targeting I'm to their system are spine. track devices the markets covering have we particularly Agency to market approval existing Brazil, regulatory and medical CompuFlo National introducing that Brazil's of pleased records the We territories. within in the junction cervical sell within lumbar, the from
this cooperation the Brazil, relationships a economy significant to for Brazil partners product presents the largest in setting Ahead and look for over stage near medical we've the ongoing successful and with commercial future. approval, leading globally, hospitals Final with and negotiations the launch. of are new in million forward institutions us. proactively announcing As people, the key ninth opportunity XXX established we
suffering chronic X.X births people and XX each year back million has from pain. over million Brazil
limited X in Independent that with areas traditional epidural million and seeking in safer we estimates resources that X partners, a procedures performed However, Epidural believe to right the treatment. training. million with research market the just with especially can by We XX% addressable alternative annually expand anesthesia are offering procedures, rural Brazil. to
strategy, also a Brazil approval in global South The the Latin an point entry America in into expansion previous FDA and our building our on in United is by milestone providing significant States. approval
portfolio. our of for and protection value multiple Europe U.S. patent property around our focused the We and IP of delivery injection systems. remain that key allowance patent receipt both and we on intellectual the broaden applications of notices drug in announced the increasing recently Lastly,
look that patients So of the build to further summarize in our benefit and the and advancing to to technology. our Medical as updates and progress and nationwide are it from strategy. and abroad. practitioners commercial safety initiatives we continuing rollout a division, more on momentum, ensuring precision providing reimbursement relates disciplined both our the this We to forward U.S. executing
U.S. is million platform. process $X.X distributors to ability second decision line previous last more in-house, the division, strategic of to able direct Dental of our our sales the from we've bringing e-commerce enhancing and preferences. This growth quarter communication $X.X to during to online increased to to their our of transition direct year. result this a period needs Turning million respond same in compared and own been create XXXX, with instead our By sales our to through channel a customers, our our
more XX% the which margin not in to only a of has year, This increased year. the in reflects cost also from the quarter XX.X% gross margins, we our second quarter improvement same have led expansion shift efficiencies to in this last team. significant gained, This service customers steady our will products sales. believe that our the we on support foundation also the have established to reliability the our by importantly, place of continue in that domestic and after quality, but provided sale the We growth value
online directly reach portal. designed to on been by targeted bolstered focus both of e-commerce has patients, campaigns and marketing renewed Our through benefits reinforcing our the purchasing customers
to continue refine U.S. efforts, we traction to market and see expect in increase the we expand As further these and shares
some due resolved, issues distributors' On allowing freight forwarders, our have the since and normal with international us operations. temporary front, these did while we been stabilize to to resume challenges encounter
reassessment Additionally, based sales our had our in impact to China comparisons. market year-over-year that the our post an in on strategy of proactive decision on
Nevertheless, year. international half and improvement both of half in last the this currently over half second believe of year of we second show that first sales year will this the
the our The for model is Dental flow. we scalable, business. about positive Looking ahead, strengthened have changes are laid designed implemented future high-margin our operations, business cash we not have that also foundation optimistic generate the to only have current but a of
profitability We our continue yield results, growth, to driving in strong will satisfaction customer the come. are and approach confident that to years and quarters
and are a inflection payment safety rate that the up, technology. at milestone the the point first CompuFlo pivotal underscores we a to of B value wrap Pipe our of following Epidural our System, grant assignment So physician Medicare for
remain momentum. committed us The combination build as driving growing shareholders our as Dental commercialization, expansion enhancing division Biologics, outcomes value we partnerships e-commerce ingredients patient our well with key Brazil, for of such necessary the Actual like our the start provide as We as to into success. of for continue the markets for reimbursement and platform to this strategy, on our
like call time, Finance, I'd At to the President, Please Keisha Harcum, Keisha. to over go detail. financials the this ahead, in go Vice over turn to